AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 22 min read$TENX

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics (Nasdaq: TENX) said Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress 2026 in late-breaking session. The company expects to report topline data in August 2026; enrollment of 230+ patients finished March 2026.

Original reporting
manilatimes.net
Published Jul 2, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$TENXBullishMed
01

Why it matters

The company advances the data-disclosure pathway by submitting an abstract for ESC 2026 and reiterating an August 2026 topline expectation, setting a concrete catalyst window for clinical-trial sentiment.

02

Market read

This is a near-term event/timeline update for a single biotech catalyst (LEVEL topline in August; ESC late-breaking presentation), useful for timing trades around clinical-news flow.

03

What to watch

Traders should monitor whether the August topline timing slips (database lock/statistical analysis) and whether any BSSR/endpoint assumptions translate into clinically meaningful effect sizes.

Relevance 7/10Novelty 6/10Timing: Ahead of ESC Congress 2026 (Aug 28-31) with topline LEVEL results expected in August.

Background

Tenax’s registrational Phase 3 LEVEL trial (TNX-103 oral levosimendan) in PH-HFpEF completed enrollment of 230+ patients in March 2026.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

Tenax says Phase 3 LEVEL trial results will be presented as a late-breaking session at ESC 2026 and expects topline data in August 2026.

Expected impact

Moderate positive bias into August as traders price the upcoming topline readout; volatility likely around abstract/database-lock milestones.

Evidence & confidence

The release is company-specific and advances the clinical-data timeline (late-breaking ESC presentation; topline expected in August), but it does not provide efficacy/safety results yet.

Market effects

Sector

Adds incremental momentum for cardiopulmonary/pharma development narratives tied to levosimendan and PH-HFpEF, but without new efficacy data it’s not a sector reset.

Regional

Primarily US-listed biotech sentiment; ESC timing may drive Europe-focused attention but no direct regional macro linkage is stated.

Global

Limited global impact beyond clinical-trial watchlists; the key is the company’s August topline window rather than a broad market event.

Counterpoint

What could challenge this read

Late-breaking presentation can still precede a mixed or underwhelming topline readout; without results, the market may overreact to scheduling rather than outcomes.

Key entities

  • company
    Tenax Therapeutics, Inc.

    Nasdaq-listed developer of levosimendan for PH-HFpEF; Phase 3 LEVEL trial topline expected in August 2026.

  • clinical_trial
    LEVEL (NCT05983250)

    Phase 3 registrational trial evaluating TNX-103 in PH-HFpEF; primary endpoint is 6-minute walk distance.

  • conference
    ESC Congress 2026

    European Society of Cardiology meeting where LEVEL data will be presented in a late-breaking session on Aug 29, 2026.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 10
$METAMed

Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides

US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.

zerohedge.com7 min
AUG 10
$TENXHighAI 8/10

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.

investing.com7 min
AUG 10
$TENXHighAI 9/10

Why is Tenax Therapeutics stock collapsing today?

Tenax Therapeutics (TENX) shares fell about 84% pre-open after its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to meet the primary endpoint for pulmonary hypertension due to heart failure with preserved ejection fraction, with a 3.5-meter least-squares mean difference and p-value 0.63. It also missed a key secondary endpoint. The company is evaluating next steps and has $118 million cash runway through mid-2028.

investing.com4 min
JUL 31
$TENXMed

TENAX THERAPEUTICS, INC. (TENX): Results of Operations and Financial Condition

TENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE N

SEC EDGAR 8-K4 min
JUL 2
$TENXMed

Tenax Therapeutics, Inc.: Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics (Nasdaq: TENX) said Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress 2026 (Aug 28-31) via a late-breaking session on Aug 29. The company expects topline results in August after database lock and statistical analysis; enrollment of 230+ patients was completed in March 2026.

finanznachrichten.de4 min
AUG 10
$NVDAMed

Nvidia, Wall Street giants partner to raise $500-billion for AI infrastructure

Nvidia partnered with six financial institutions, including Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR, to launch AI compute financing platforms targeting more than $500 billion in third-party capital for AI infrastructure. The plan aims to expand access to Nvidia-based infrastructure for developers, enterprises, governments and cloud providers. Nvidia did not disclose terms or timelines.

theglobeandmail.com6 min